ASSESSMENT OF WIHDRAWAL PERIOD OF OXYTETRACYCLINE POST TREATMENT OF PIGS AND POULTRY IN ROMANIA-Reference-Cited by-同舟云学术

ASSESSMENT OF WIHDRAWAL PERIOD OF OXYTETRACYCLINE POST TREATMENT OF PIGS AND POULTRY IN ROMANIA

Published:2023-12-15 Issue:3 Volume:66 Page:48-52
ISSN:1454-7406
Container-title:Scientific Papers Journal VETERINARY SERIES
language:
Short-container-title:SPJVS

Author:

,BELOUS Madalina^ORCID

Abstract

The presence of antimicrobial residues in animal products must be lower than maxim residue level (MRL), other way may have adverse effects on consumer health such as allergic reactions and resistance development. Withdrawal periods are used to avoid animas to be slaughter before the concentration of MRL declines with respect for public health’s and waste food. The paper investigates the use of oxytetracycline in pigs and poultry with a focus on the differences on the withdrawal periods for different products used in Romania. The original question is whether compliance with the withdrawal period can be used to judge compliance with the MRL and its applicability for pigs and poultry industry.

Publisher

Universitatea de Ştiinţele Vieţii "Ion Ionescu de la Brad" din Iaşi

Reference21 articles.

1. "1. Daniel Hjorth Lund, Jesper Valentin Petersen, Boris Antunovic, Madalina Belous, Silvia Bonardi, Rosa Maria García-Gimeno, Ian Jenson, Arja H. Kautto, Michał Majewski, Derk Oorburg, Ioannis Sakaridis, Alexandrina Sirbu, Madalena Vieira-Pinto, Ivar Vågsholm, Lis Alban (2023). - Withdrawal periods after treatment of pigs with oxytetracycline in- and outside the European Union, Food Control, Volume 155, 2024, 110071, ISSN0956-7135, https://doi.org/10.1016/j.foodcont.2023.110071

2. 2. EU Commission. (2018). EU Regulation 2018/782 https://eur-lex.europa.eu/legalcontent/ EN/TXT/?uri=CELEX%3A32018R0782.

3. 3. EU Commission. (2019a). EU Delegated Regulation 2019/2090 https://eur-lex.europa. eu/legalcontent/ EN/TXT/?uri=CELEX%3A02019R2090- 20221019&qid=1685537889687.

4. 4. EU Council. (1996). Council Directive 96/23/EC https://eur-lex.europa.eu/legalcontent/ EN/TXT/?uri=CELEX%3A01996L002320130701&qid=1685537965810.

5. 5. European Medicines Agency. (2012). Guideline on the approach to establish a pharmacological ADI. Guideline on the approach to establish a pharmacological ADI. EMA/CVMP/SWP/355689/2006, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-approach-establish pharmacological-acceptable-daily-intake_en.pdf.